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Numerous rheological and microvascular alterations characterize the vascular pathology in patients with type 2
diabetes mellitus (T2DM). This study investigated effects of vildagliptin in comparison to glimepiride on retinal
microvascular blood flow and erythrocyte deformability in T2DM.
Fourty-four patients with T2DM on metformin monotherapy were included in this randomized, exploratory study
over 24 weeks. Patients were randomized to receive either vildagliptin (50 mg twice daily) or glimepiride
individually titrated up to 4 mg in addition to ongoing metformin treatment. Retinal microvascular blood flow (RBF)
and the arteriolar wall to lumen ratio (WLR) were assessed using a laser doppler scanner. In addition, the
erythrocyte elongation index (EI) was measured at different shear stresses using laserdiffractoscopy.
Both treatments improved glycaemic control (p < 0.05 vs. baseline; respectively). While only slight changes in RBF
and the WLR could be observed during treatment with glimepiride, vildagliptin significantly increased retinal blood
flow and decreased the arterial WLR (p < 0.05 vs. baseline respectively). The EI increased during both treatments
over a wide range of applied shear stresses (p < 0.05 vs. baseline). An inverse correlation could be observed
between improved glycaemic control (HbA1c) and EI (r = −0.524; p < 0.0001) but not with the changes in retinal
microvascular measurements.
Our results suggest that vildagliptin might exert beneficial effects on retinal microvascular blood flow beyond
glucose control. In contrast, the improvement in erythrocyte deformability observed in both treatment groups,
seems to be a correlate of improved glycaemic control.
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Type 2 diabetes mellitus (T2DM) is associated with
numerous vascular and hemorheological abnormalities
which merge together in an unproportional high risk for
the development of micro- and macrovascular complica-
tions like retinopathy, nephropathy, neuropathy, or cardio-
vascular disease. The assessment of retinal microvascular
architecture and the investigation of retinal arterial blood
flow allows to detect early vascular abnormalities in* Correspondence: thomasf@ikfe.de
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distribution, and reproduction in any mediumpatients with T2DM even before the clinical manifestation
of diabetic retinopathy [1-3]. In recent studies, a close
association could be found between retinal micro-
vascular abnormalities and an increased risk for the
development of nephropathy, neuropathy, myocardial
infarction, or stroke [4-8].
Recently, dipeptidyl-peptidase IV (DPP-IV) inhibitors
have been introduced in the treatment of T2DM. A couple
of studies suggested pleiotropic effects beyond metabolic
control for this class of drugs. Treatment with DPP-IV
inhibitors was found to improve myocardial and endothelial
function, to improve blood lipids, to lower blood pressure
and to improve markers of renal function [9-16]. In vitroentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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lial cells, and the inhibition of DPP-IV reduced the micro-
vascular tone through direct mediation of the nitric oxide
system [17]. Therefore, it seems conceivable that glucose-
independent effects of DPP-IV inhibition might be mediated
through GLP-1 receptor signalling and /or direct inhibition
of the enzyme DPP-IV in vascular, renal, or retinal cells.
Based on the different mode of action, these effects might
not be applicable to other antidiabetic treatments like
K-ATP-channel blocker such as sulfonylureas.
The aim of this exploratory study was to investigate
the effect of vildagliptin in comparison to glimepiride as
add-on to metformin on retinal microvascular blood
flow, retinal microvascular architecture and erythrocyte
deformability in type 2 diabetic patients inadequately
controlled on metformin monotherapy.
Methods
This single-centre, randomized, open-label, parallel study
compared microvascular and hemorheological effects of
treatment with either vildagliptin or glimepiride in type 2
diabetic patients pre-treated with metformin. To be consid-
ered eligible, patients had to be aged 30–80 years with an
HbA1c in the range of 6.5 to 9.5%. The main exclusion cri-
teria were myocardial infarction or stroke within 6 months
prior to study enrolment; impaired hepatic or renal func-
tion; moderate or proliferative diabetic retinopathy, more
than one unexplained episode of severe hypoglycemia
within 6 months; pre-treatment with other anti-diabetic
drugs with the exception of metformin within the last
3 months and uncontrolled hypertension (systolic blood
pressure >160 and/or diastolic blood pressure >90 mmHg).
The study was performed in compliance with Good
Clinical Practice and all applicable national laws and regula-
tions. All patients provided written informed consent and
the study was approved by an appropriate independent
ethics committee.
Eligible patients were randomized to vildagliptin or
glimepiride in a 1:1 ratio. Patients received 50 mg
vildagliptin twice daily. Glimepiride was administered in
the morning with an individual dose titration in the
range of 0.5 – 4 mg to achieve best possible glycaemic
control as judged by the investigator. At baseline, after
12 and 24 weeks of treatment, patients entered the study
site in the morning after an overnight fast of at least
eight hours. Fasting blood samples were obtained for the
measurement of blood glucose, HbA1c, adiponectin, and
the determination of erythrocyte deformability. In
addition, all patients underwent retinal fundoscopy and
retinal microvascular assessments.
Measurement of erythrocyte deformability
Blood cell deformability was measured using a laser-
assisted optical rotational cell analyzer by determining theelongation index (EI). Laserdiffractoscopy was performed
using the Rheodyn SSD shear stress diffractometer
(Myrenne GmbH, Roetgen, Germany). The method of
laserdiffractoscopy has been described in detail previously
[18]. The applied shear stress was electronically regulated
and consists of 8 increasing shear stress ranges (0.3; 0.6;
1.2; 3; 6; 12; 30; 60 Pa). The measurement detects scattered
light intensities along orthogonal axes (A, B) of red blood
cells within the laser diffraction light cone. The erythrocyte
elongation index (EI) was calculated by the following equa-
tion: EI(%) = ((A −B)/(A + B)) * 100. To compare the EI
over the applied shear stress range between both treatment
groups, the area under the curve from 0.3 to 60 Pa
(AUC0.3–60) was calculated using the trapezoidal method.
Measurement of retinal microvascular blood flow (RBF)
and retinal arteriolar wall to lumen ratio (WLR)
Retinal capillary blood flow was assessed using scanning
laser doppler flowmetry at 670 nm (Heidelberg Retina
Flowmeter, Heidelberg Engineering, Germany). A retinal
sample of 2.56 × 0.64 × 0.30 mm was scanned within
2 seconds at a resolution of 256 points × 64 lines × 128
lines. The confocal technique of the device ensured that
only the capillary blood flow of the superficial retinal layer
of 300 μm was measured. Measurements were performed
in the juxtapapillary area of both eyes, 2 to 3 mm
temporally to the optic nerve; the average from 3 singular
measurements was taken.
Analysis of perfusion images was performed offline
with automatic full-field perfusion imaging analysis. This
led to a perfusion map excluding vessels with a diameter
of >30 μm, without lines with saccades, and without
pixels with inadequate reflectivity. The mean retinal
capillary blood flow was calculated in the area of interest
and expressed as arbitrary units.
Analysis of vessel diameters was performed offline
with automatic full field perfusion imaging analysis (SLDF
version 3.7) [19,20]. Outer arteriole diameter (AD) was
measured in reflection images, and lumen diameter (LD)
was measured in perfusion images. The wall to lumen ratio
(WLR) was calculated as (AD-LD)/LD.
The laser scanning records were stored electronically
and sent to a central reading centre (Interdisciplinary
Centre for Ophthalmic Preventive Medicine and Imaging
(IZPI) of the Friedrich-Alexander-University Erlangen-
Nürnberg, Germany), for the measurement of retinal
microvascular blood flow and the calculation of the retinal
wall to lumen ratio (WLR). This reading centre was blinded
for all other study procedures.
Laboratory measurements
Blood glucose levels were determined using an electro-
chemical biosensor (Hitado, Möhnesee, Germany). Plasma
adiponectin was measured using ELISA (total human
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HPLC (Menarini Diagnostics, Neuss, Germany).
Statistical analysis
This study was designed as an exploratory study aimed to
provide new data for thesis generation. No a priory con-
firmatory sample size estimation has been performed. All
study endpoints have been analyzed with equal priority in
a non-confirmatory, exploratory sense. RBF and WLR
were assessed in a central reading centre in a blinded fash-
ion. All other study endpoints were assessed in an open
label approach. All study results were evaluated using
primarily descriptive statistics. Inferential statistics was
used to compare results from baseline to endpoint within
both treatment groups. Differences in means of study
endpoints were tested by Student’s t-test. In case of not
equal variances in the data, the results of the Welch
approximation was taken into account as result of the
unpaired comparison. Results are presented as mean ± SD.
Significance was set at a p-value less than 0.05. Data pro-
cessing was performed with the software modules of SPSS
(Statistical package for analysis in social sciences, release
19.0, SPSS Inc., Chicago, USA).
Results
Table 1 summarizes the demographics and baseline
characteristics for the 44 patients included in the final
analysis. Both study groups were comparable with regard
to gender, age, HbA1c, and BMI. Patients in the
vildagliptin group were found to have a slightly longer
duration of T2DM compared to the patients in the
glimepiride group.
As shown in Table 2, fasting blood glucose and HbA1c
levels decreased continuously in both study groups from
baseline to the end of the observational period. In patients
treated with vildagliptin a reduction in body weight and
an increase in adiponectin levels could be observed, while
patients treated with glimepiride increased body weight
with no change in adiponectin levels.
In both groups, an increase in retinal blood flow (RBF)
and a decrease in the retinal arteriolar wall to lumen ratio
(WLR) could be observed (Figures 1 and 2). After 24 weeksTable 1 Baseline demographics and baseline
characteristics of the study groups
Glimepiride Vildagliptin
n 22 22
Male / female 13 / 9 15 / 7
Age (years) 60 ± 7 57 ± 9
Duration of diabetes (years) 6.1 ± 4.4 8.4 ± 9.0 $
HbA1c (%) 7.3 ± 0.6 7.4 ± 0.7
BMI (kg/m2) 33.3 ± 6.7 34.6 ± 5.9
mean ± SD; $ = p < 0.05 in between both groups.of treatment the increase in RBF and the decrease in
the WLR reached statistical significance during treat-
ment with vildagliptin, but not during treatment with
glimepiride. No association was found between
changes in glucose, HbA1c, or adiponectin levels with
the parameters of RBF or arteriolar WLR.
In contrast to the findings in retinal blood flow, the
erythrocyte elongation index (EI) improved significantly in
both treatment groups over a wide range of applied shear
stresses (Table 3). The area under the curve calculated for
the shear stress range between 0.3 and 60 Pa increased
from 2536 ± 228 to 2682 ± 240 AU*min (p < 0.0001)
during treatment with glimepiride and from 2568 ± 196 to
2623 ± 210 AU*min (p < 0.0001) during treatment with
vildagliptin. A linear inverse correlation could be
observed between fasting blood glucose levels and the
EI (r = −0.417; p < 0.0001), and between the HbA1c
and the EI (r = −0.524; p < 0.0001). A slight positive
correlation was found between adiponectin levels and
the EI (r = 0.31; p < 0.001).
No severe hypoglycemic event was observed during
the study. Symptomatic hypoglycemic episodes were
reported in 29 cases during treatment with metformin
and glimepiride and in 2 cases during treatment with
metformin and vildagliptin. Both treatments were overall
well-tolerated. No serious adverse event with causal rela-
tionship was reported during the study. Infections were
recorded in 17.4% of patients during treatment with met-
formin and glimepiride and in 18.2% during treatment
with metformin and vildagliptin. Gastrointestinal disor-
ders were reported in 17.4% of patients during treatment
with metformin and glimepiride and in 27.3% during
treatment with metformin and vildagliptin.
Discussion
The burden of T2DM is driven by the development of
micro- and macrovascular complications. Vascular dys-
function, changes in the vascular architecture, and
hemorheological alterations are early features associated
with obesity, metabolic syndrome and the development
of T2DM. Remodeling of arterioles and small arteries is
an early feature in retinal vascular pathology, and are often
found even before the clinical diagnosis of diabetic retinop-
athy [1,4,21]. The retina offers the unique approach to
visualize human microcirculation non-invasively and safely
in vivo. Retinal vascular damage was shown to be predictive
for the development of micro- and macrovascular compli-
cations [5,6,22-24]. A decreased retinal blood flow could be
observed in T2DM in association with diabetic nephropa-
thy [25], and an increase in the wall to lumen ratio of
retinal arteries was found in association with increased
blood pressure, and in patients with a history of cerebrovas-
cular or cardiovascular events [7,8,26]. In a recent study, it
was suggested that increased retinal arteriolar WLR may be
Table 2 Investigational parameters at baseline, after 12 and 24 weeks of treatment in the observational groups
Baseline 12 weeks 24 weeks
Glimepiride Vildagliptin Glimepiride Vildagliptin Glimepiride Vildagliptin
HbA1c (%) 7.28 ± 0.59 7.41 ± 0.74 6.70 ± 0.50 * 6.95 ± 0.82 * 6.57 ± 0.45 * 6.74 ± 0.75 *
Fasting BG (mmol/L) 8.2 ± 1.9 8.4 ± 1.5 7.0 ± 1.2 * 7.6 ± 1.9 7.0 ± 1.2 * 7.4 ± 1.4 *
Adiponectin (μg/mL) 5.6 ± 3.1 5.0 ± 3.5 5.4 ± 2.8 5.5 ± 4.1 5.7 ± 2.7 5.7 ± 4.1 *
Body weight (kg) 93.7 ± 19.6 99.3 ± 14.9 94.4 ± 18.9 98.7 ± 15.0 95.5 ± 19.0 97.6 ± 14.3 *
RBF (AU) 74.2 ± 5.3 75.1 ± 5.8 74.7 ± 6.9 75.3 ± 5.8 76.1 ± 7.6 77.9 ± 5.9 *
WLR (AU) 0.47 ± 0.08 0.46 ± 0.06 0.45 ± 0.09 0.43 ± 0.07 0.43 ± 0.08 0.40 ± 0.06 *
EI AUC0.3–60 (AU*min) 2536 ± 228 2568 ± 196 2505 ± 256 2570 ± 170 2682 ± 240 * 2623 ± 210 *
BG =blood glucose; RBF =Retinal blood flow; WLR = arteriolar wall to lumen ratio; EI AUC0.3–60 = area under curve for the elongation index in the shear stress
range of 0.3-60 Pa; mean ± SD; * = p < 0.05 vs. baseline.
Berndt-Zipfel et al. Cardiovascular Diabetology 2013, 12:59 Page 4 of 7
http://www.cardiab.com/content/12/1/59a reflection of an altered endothelial-mediated release of
nitric oxide [27].
Recently, GLP-1 receptor agonists and DPP-IV
inhibitors have been introduced in the treatment of
T2DM. Treatment with the DPP-IV inhibitor
vildagliptin was shown to be well tolerated, to
reduce glucose excursions, and to improve the func-
tional capacity of beta cell [28-30]. Apart from the
metabolic effects, treatment with DPP-IV inhibitors
is supposed to exert several pleiotropic activities
which might modulate vascular function in T2DM
[31,32]. GLP-1 receptors are widely expressed in
pancreatic, kidney, lung, brain, myocardial, and
endothelial cells. There is increasing evidence that
GLP-1 might improve endothelial and vascular func-
tion at least in part through nitric oxide dependent
pathways [10,15,17,33,34]. In contrary, treatment
with vildagliptin was found without beneficial effect
on cardiac function in long term post-MI remodeling
in rodents [35].
In our study, treatment with vildagliptin in T2DM
resulted in a significant improvement in RBF and aFigure 1 Mean change from baseline in retinal blood flow (RBF)
during glimepiride and vildagliptin treatment after 12 and
24 weeks of treatment (□ = glimepiride; ■ = vildagliptin;
mean ± SEM; * = p < 0.05 vs. baseline).significant decrease in the retinal arteriolar WLR.
These effects on retinal microcirculation became ap-
parent in between 12 and 24 weeks of treatment with
vildagliptin, indicating some time consuming struc-
tural changes in the microvascular system. It seems
conceivable, that treatment with vildagliptin interferes
with vascular remodeling of small arteries in patients
with T2DM. In rodents, GLP-1 receptor activation
has been associated with reductions in intima hyper-
plasia and PDGF-induced vascular smooth muscle cell
proliferation [36,37]. The clinical significance of the
observed improvements in retinal microvascular blood
flow and vascular architecture with regard to the de-
velopment of diabetic retinopathy or other organ
damage in T2DM remains unclear and needs to be
clarified in pursuing studies. Nevertheless, our results
are in accordance with numerous other investigations
indicating an improvement in the vascular risk profile
during treatment with GLP-1 receptor agonists or
DPP-IV inhibitors [15,38-41]. Despite comparable
glycaemic control, these effects were much weaker
during treatment with glimepiride, suggesting effectsFigure 2 Mean change from baseline in retinal arteriolar wall
to lumen ratio (WLR) during glimepiride and vildagliptin
treatment after 12 and 24 weeks of treatment (□ = glimepiride;
■ = vildagliptin; mean ± SEM; * = p < 0.05 vs. baseline).
Table 3 Erythrocyte deformability – elongation index (EI) at different shear stress rates at baseline and after 12 and
24 weeks of treatment in both treatment groups
Baseline 12 weeks 24 weeks
Shear stress (Pa) Glimepiride Vildagliptin Glimepiride Vildagliptin Glimepiride Vildagliptin
0.3 0.65 ± 0.68 0.86 ± 0.45 0.93 ± 0.80 0.87 ± 0.63 1.65 ± 1.40 * 1.54 ± 0.91 *
0.6 2.66 ± 1.14 2.55 ± 1.24 2.37 ± 1.37 2.65 ± 1.34 3.76 ± 2.13 3.67 ± 1.73 *
1.2 8.53 ± 2.25 8.80 ± 2.00 7.96 ± 2.38 8.79 ± 2.29 10.11 ± 2.66 * 10.24 ± 2.90 *
3 20.89 ± 3.60 21.71 ± 3.24 20.09 ± 3.68 21.53 ± 3.28 24.13 ± 3.74 * 23.95 ± 3.14 *
6 30.50 ± 3.95 31.33 ± 3.45 29.81 ± 4.17 31.15 ± 3.25 33.80 ± 4.13 * 33.20 ± 3.32 *
12 38.62 ± 4.01 39.36 ± 3.34 37.95 ± 4.33 39.28 ± 3.02 41.37 ± 4.12 * 40.59 ± 3.33 *
30 46.43 ± 3.86 47.07 ± 3.38 45.94 ± 4.47 47.14 ± 2.82 48.80 ± 4.13 * 47.71 ± 3.59
60 50.12 ± 3.86 50.75 ± 3.48 49.70 ± 4.36 50.89 ± 2.97 52.69 ± 4.25 * 51.32 ± 4.05
mean ± SD; * = p < 0.05 vs. baseline.
Berndt-Zipfel et al. Cardiovascular Diabetology 2013, 12:59 Page 5 of 7
http://www.cardiab.com/content/12/1/59of vildagliptin on retinal microvascular blood flow
which go beyond glucose control.
Another important parameter in microvascular blood
flow is blood viscosity, mainly driven by the elastic prop-
erties of red blood cells. The measurement of erythro-
cyte deformability reflects the ability of the cells to
deform while entering small nutritive capillaries where
the inner vessel lumen becomes less than the outer
diameter of the blood cells, and the erythrocyte needs to
assimilate while passing the nutritive capillary network
[42,43]. Impaired erythrocyte deformability in T2DM is
reported in numerous studies using different technolo-
gies [44-47], leading to the suggestion that impaired
erythrocyte deformability, at least partially, accounts for
the impaired tissue nutrition observed in these patients.
In a recent investigation, it was shown that patients with
T2DM and coronary artery disease present with im-
paired erythrocyte elasticity compared to those patients
with coronary artery disease without T2DM [48]. An
increase in blood glucose stimulates the glycosylation of
the skeletal proteins beta-spectrin, ankyrin, and protein
4.2, while at the same time spectrin is damaged by
oxidation [49]. Erythrocytes in patients with T2DM
further show a decrease of the Na+K+-ATPase and the
Ca2+-ATPase activity [50,51]. These alterations affect the
membrane bilayer of erythrocytes in terms of their fluidity
and might account for the increased rigidity of the cells.
The role of elevated glucose levels on erythrocyte
deformability has been described controversially [45,48,52].
The reasons for these discrepancies are matter of debate
and might be explained by different patient populations or
study designs. In our study, twenty-four weeks of treatment
with glimepiride and vildagliptin improved erythrocyte
deformability in patients with T2DM. An inverse correl-
ation could be observed between erythrocyte deformability
and fasting glucose levels (r = −0.417; p < 0.0001) as well as
HbA1c (r = −0.524; p < 0.0001). Therefore, lowering of
blood glucose levels in T2DM seems to improve the elasticproperties of the erythrocytes independent from the kind
of treatment.
In accordance with a previous study, we found an
inverse correlation between plasma adiponectin levels
and erythrocyte deformability (r = 0.31; p < 0.001) [52].
In hypertensive patients an inverse relationship could be
observed between adiponectin levels and erythrocyte
membrane fluidity as measured by an electron paramag-
netic resonance and spin labeling method [53]. In
addition, this study demonstrated decreased membrane
fluidity in association with reduced plasma nitric oxide
metabolites. Because the deformability of erythrocytes is
highly dependent on their membrane fluidity [54,55], the
reduction in membrane fluidity associated with low
adiponectin levels might contribute to the alterations
in blood rheology and tissue perfusion in patients
with T2DM.
In conclusion, our study suggests that treatment
with vildagliptin exert beneficial effects on retinal
microvascular blood flow and retinal microvascular
architecture, which could not be explained merely by
improved metabolic control. In contrast, the augmen-
tation in erythrocyte elasticity seems to correlate with
improved glycaemic control and are found independent
from the kind of pharmacological intervention. Treatment
with vildagliptin in patients with T2DM seem to pro-
vide beneficial effects on microvascular blood flow
which could be explained by glucose dependent and
independent mechanisms.
Limitations of the study
Our study was designed as an exploratory study
without a priory sample size calculation. All results
have to be interpreted with equal magnitude in a
non-confirmatory sense. Further pursuing studies
have to confirm our results and to evaluate their
clinical significance for the development of vascular
complications in T2DM.
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